Summary
The absolute bioavailability of nicotine administered nasally, as drops to the nasal conchae and nasal septum, and as a nasal spray, has been studied in eight healthy volunteers. Single nasal doses of 1 mg nicotine were given and plasma concentrations of nicotine were followed for 6 h.
Compared to an intravenous infusion of nicotine, the bioavailability of the nasal administrations was 60 to 75%. The rate of absorption was fast, the maximum concentration being reached after about 10 min.
In the present study, there was no significant difference in the rate or extent of absorption between the different nasal treatments.
Similar content being viewed by others
References
Benowitz N, Jacob P, Jones RT, Rosenberg J (1982) Inter-individual variability in the metabolism and cardiovascular effects of nicotine in man. J Pharmacol Exp Ther 221: 368–372
Benowitz NL, Jacob P (1984) Daily intake of nicotine during cigarette smoking. Clin Pharmacol Ther 35: 499–504
Russel MAH, Jarvis MJ, Feyerabend C, Fernö O (1983) Nasal nicotine solution; a potential aid to give up smoking? Br Med J 286: 683–684
West RJ, Jarvis MJ, Russel MAH, Feyerabend C (1984) Plasma nicotine concentrations from repeated doses of nasal nicotine solutions. Br J Addiction 79: 443–445
Olsson P, Kuylenstierna F, Johansson C-J, Gunnarsson PO, Bende M (1991) Pharmacokinetics of nicotine after intranasal administration. In: Adlkofer F (ed) Effects of nicotine on biological systems. Advances in Pharmacological Sciences. Birkhäuser, Basel, pp 57–61
Freestone DS, Weinberg AL (1976) The administration of drugs and vaccines by the intranasal route. Br J Clin Pharmacol 3: 827–830
Edsbäcker S, Andersson K-E, Ryrfeldt Å (1985) Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man. Eur J Clin Pharmacol 29: 477–481
Hussain A, Foster T, Hirai S, Kashihara T, Batenhorst R, Jones M (1980) Nasal absorption of propranolol in humans. J Pharm Sci 69: 1240
McMartin C, Hutchinson LEF, Hyde R, Peters GE (1987) Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J Pharm Sci 76: 535–540
Stratford RE, Lee VHL (1986) Amino peptidase activity in homogenates of various absorptive mucosae in the albino rabbit: implications in peptide delivery. Int J Pharm 30: 73–82
Harris AS, Nilsson IM, Wagner ZG, Alkner U (1986) Intranasal administration of peptides: nasal deposition, biological response, and absorption of desmopressin. J Pharm Sci 75: 1085–1088
McLean JA, Bacon JR, Mathews KP, Thrall JH, Banas JM, Hedden J, Bayne NK (1984) Distribution and clearance of radioactive aerosol on the nasal mucosa. Rhinology 22: 65–75
Hardy JG, Lee SW, Wilson CG (1985) Intranasal drug delivery by sprays and drops. J Pharm Pharmacol 37: 294–297
Chien YW (1985) Transnasal systemic medications. Fundamentals, developmental concepts and biomedical assessments. Elsevier Science, Amsterdam
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Johansson, CJ., Olsson, P., Bende, M. et al. Absolute bioavailability of nicotine applied to different nasal regions. Eur J Clin Pharmacol 41, 585–588 (1991). https://doi.org/10.1007/BF00314989
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00314989